These programs can be especially helpful for uninsured or underinsured patients
Eli Lilly is evaluating its lead asset, tirzepatide , in phase III obesity drug clinical trials for the reduction of morbidity and mortality in obesity
However, the complaints that do exist reveal operational gaps, primarily around shipping logistics, billing communication, and transparency about formulation changes, that are worth considering before enrolling
The FDA subsequently approved Vimkunya in February 2025
The most reasonable choice depends on the clinical objective, formulation quality, route, tolerance, convenience and evidence proportional to the claim being made